Driehaus Capital Management’s Travere Therapeutics TVTX Stock Holding History

Driehaus Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$38.1M	Buy	1,282,518 +381,114	+42%	+$11.4M	0.28%	124
2025 Q4	$34.4M	Buy	901,404 +193,944	+27%	+$6.31M	0.23%	140
2025 Q3	$16.9M	Buy	+707,460	New	+$13.3M	0.12%	222
2025 Q2	–	Sell	-2,767,693	Closed	-$49.6M	–	505
2025 Q1	$49.6M	Buy	2,767,693 +549,718	+25%	+$11.2M	0.48%	61
2024 Q4	$38.6M	Buy	2,217,975 +1,904,733	+608%	+$33.7M	0.32%	103
2024 Q3	$4.38M	Buy	+313,242	New	+$3.26M	0.04%	285
2015 Q3	–	Sell	-13,449	Closed	-$446K	–	616
2015 Q2	$446K	Buy	+13,449	New	+$368K	0.02%	472

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Driehaus Capital Management's TVTX Position: Q1 2026 in Review

Driehaus Capital Management increased its Travere Therapeutics (TVTX) stake by 42% in Q1 2026, buying an estimated $11.4M and bringing the position to 1,282,518 shares worth $38.1M. The position accounts for 0.28% of the portfolio, ranked #124.

Driehaus Capital Management first reported a position in TVTX in Q2 2015 and has held it in 7 quarters since. The position peaked at $49.6M in Q1 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

Driehaus Capital Management held 1,282,518 shares of Travere Therapeutics worth $38.1M as of Q1 2026.
Driehaus Capital Management bought 381,114 Travere Therapeutics shares in Q1 2026, an estimated $11.4M.
Travere Therapeutics made up 0.28% of Driehaus Capital Management's portfolio in Q1 2026, its #124 holding.
Driehaus Capital Management first reported a position in Travere Therapeutics in Q2 2015 and has held it in 7 quarters since.
Driehaus Capital Management's Travere Therapeutics position peaked at $49.6M in Q1 2025.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Driehaus Capital Management's 13F filing for Q1 2026, filed 15 May 2026.